PIM Kinases in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is the second most common hematologic malignancy in the United States. Eventually, all myeloma patients will relapse and develop resistance to currently available agents. There is an unmet medical need to identify novel therapeutic targets. PIM kinases play an import...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jian, Chu, Emily, Kang, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428354/
https://www.ncbi.nlm.nih.gov/pubmed/34503111
http://dx.doi.org/10.3390/cancers13174304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428354/
https://www.ncbi.nlm.nih.gov/pubmed/34503111
http://dx.doi.org/10.3390/cancers13174304

Ejemplares similares